This is important, especially for those patients who had significant CE findings. Another difficulty encountered is that some insurers which are adverse to costs do not easily approve performance of EAB because it does not appear in the mandatory health plan POS. This is similar to problems encountered in the cases of vascular lesion management with argon plasma coagulation.
Otra dificultad radica en que algunas aseguradoras no autorizan fácilmente por costos la realización de EAB, al no encontrarse en el plan obligatorio de salud POS, como en los casos de manejo de lesiones vasculares con coagulación con argón plasma, y el paciente persiste con sangrado GI.